Purpose of review ADAMTS13 is a zinc-containing metalloprotease that cleaves von Willebrand factor (VWF). Deficiency of plasma ADAMTS13 activity is accountable for a potentially fatal blood disorder thrombotic thrombocytopenic purpura (TTP). Understanding of ADAMTS13-VWF interaction is essential for developing novel treatments to this disorder.
INTRODUCTION
ADAMTS13, a circulating metalloprotease, was first cloned and identified as a member of A Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats (ADAMTS) family in 2001 [1] [2] [3] . It is primarily synthesized in hepatic stellate cells [4] [5] [6] [7] , but is also found in other cells including endothelial cells [8, 9] , and megakaryocytes or platelets [10, 11] . ADAMTS13 is secreted into plasma as a constitutively active enzyme at a plasma concentration of, approximately, 1 mg/ml [12] [13] [14] . It cleaves a large adhesive glycoprotein, von Willebrand factor (VWF), that plays an essential role in primary hemostasis by recruiting platelets to the site of vessel injury [15] . VWF is synthesized in vascular endothelial cells and megakaryocytes as a multimeric protein and stored in Weibel-Palade bodies of endothelial cells and the a-granules of platelets [16] [17] [18] . Plasma VWF concentration is, approximately, 10 mg/ml. Newly released VWF forms ultra large 'string-like' structures tethered to the cell surface that are subsequently cleaved by ADAMTS13 [19] [20] [21] .
The proteolytic cleavage of ultra large VWF by ADAMTS13 is essential for maintaining the delicate balance between hemostasis and thrombosis. The inability to cleave ultra large VWF due to severe deficiency of ADAMTS13 activity results in a potentially fatal blood disorder thrombotic thrombocytopenic purpura (TTP) [22 & ]. TTP can be either the result of inherited mutations in ADAMTS13, or the result of the development of autoantibodies directed against ADAMTS13 [1, 23] . The absence of VWF cleavage allows for the accumulation of ultra large VWF and the aggregation of platelets that eventually cause the occlusion of arterioles and capillaries [1, [23] [24] [25] [26] [27] [28] . Moreover, the reduced plasma ADAMTS13 activity and increased plasma VWF are risk factors for the development of other arterial and inflammatory diseases, including myocardial infarction [29] [30] [31] , ischemic stroke [32] [33] [34] , preeclampsia [35] , and cerebral malaria [36] [37] [38] [39] [40] . Therefore, a better understanding of the functional mechanisms and structures of ADAMTS13 will provide novel tools for diagnosis and treatment of these potentially fatal human diseases. In this review, we will provide comments about the recent advances in our understandings of ADAMTS13 and VWF interactions.
STRUCTURE AND FUNCTION
The ADAMTS family proteases are zinc-containing metalloproteases [41] [42] [43] that, unlike ADAM family proteases, are not membrane bound due to the lack of a membrane-anchor domain [44, 45] . ADAMTS13, similar to other ADAMTS proteases, is comprised of a metalloprotease domain, a disintegrin-like domain, the first thrombospondin type 1 repeat, a cysteinerich domain, and a spacer domain (Fig. 1) [1-3,7] . The C-terminal regions of ADAMTS proteases are more variable with an additional seven thrombospondin type 1 (TSP-1) repeats and two CUB (the Complement components C1r and C1s, sea urchin protein Uegf, and Bone morphogenetic protein-1) domains for ADAMTS13 ( Fig. 1) [24, 45, 46] .
The propeptide on ADAMTS13 is only one-fifth of the length of a typical ADAMTS propeptide [24, 47, 48] , which functions as a molecular chaperone and maintains the latency of newly synthesized ADAMTS proteases. This function of the propeptide
KEY POINTS
ADAMTS13 cleaves VWF and is essential for hemostasis.
While the metalloprotease domain contains the catalytic site, it alone is not sufficient to cleave VWF. Other ancillary domains, including the disintegrin-like domain, the first thrombospondin type 1 repeat, the cysteine-rich domain, and the spacer domain are all required for efficient catalysis of VWF to occur.
The CUB domains of ADAMTS13 may have a negative regulatory function by blocking the spacer-VWF A2 domain interaction.
Autoantibody epitope mapping may help to identify an ADAMTS13 variant that has catalytic activity in the presence of autoantibodies. in ADAMTS13 is absent; the enzymatic function and expression levels are normal with or without a propeptide [49] .
The first ADAMTS13 domain is the metalloprotease, of which there are no crystal structures. However, closely related ADAMTS/ADAM proteases have been crystalized, and these serve as a functional and a structural template [50] [51] [52] 53 & ]. This domain is characterized by the perfectly conserved, adamalysin/reprolysin type, zinc-binding sequence (HEXXHXXGXXHD) [2] . When this zinc-binding sequence is absent, the protein does not have proteolytic activity [54] . This catalytic site is further characterized by a conserved downstream methionine residue. This 'Met-turn' creates a tight turn, important to the structure of the active site, which possibly acts as a hydrophobic base beneath the zinc ion [44, 55] . Between this conserved methionine and catalytic site, there is also a well conserved cysteine residue of unknown function [45, 46] .
Zinc-coordinating and calcium-binding residues control the cleavage activity of ADAMTS13 [56] . The zinc cation must be bound for enzymatic activity [57] . ADAMTS13 activity includes the binding of three calcium ions [2, 46, 57, 58] . Calcium binding to the calcium three site (Asp182, Asp187, and Glu212) is essential for the structural integrity of the proteolytic site [57] . A water molecule, polarized by Glu225, is part of the conserved zinc-binding sequence, and is stabilized by the zinc ion. The hydroxide molecule created from the water molecule is hypothesized to nucleophilically attack the backbone carbonyl group between the residues Tyr1605-Met1606 allowing for the hydrolysis of that bond [56, 59] .
The metalloprotease domain alone does not have the ability to bind with specificity to VWF or to cleave at the VWF Tyr1605-Met1606 cleavage site [60, 61] . The noncatalytic domains are necessary for substrate specificity [62] . Yet, the metalloprotease alone does exhibit cleavage activity but at a nonspecific location on VWF after 16-24 h of incubation [60] . Within the metalloprotease domain, residues Asp252 and Pro256 interact with Met1606, a residue in the cleave site on VWF ( Fig. 2a ) [63] . Also essential to the metalloprotease domain's protease activity are several hydrophobic residues on ADAMTS13 together to bind to VWF [64] . In addition, residue Leu1603 on VWF, when modified has a greater negative impact, more than 100-fold activity decrease, than either of the cleavage site residues [64] . It is proposed that Leu1603 interacts with residues near the zinc ion allowing for proper cleavage of the Tyr1605-Met1606 bond (Fig. 2) [64] .
The second domain on ADAMTS13 is the disintegrin-like domain. It is named for the primary sequence similarity to the snake venom disintegrins. The disintegrin domain in ADAMTS13 lacks the hallmark cysteine signature or the RGD (arginine, glycine, asparagine) motif [45, 65] . The metalloprotease domain and the disintegrin domain are functionally coupled [60, 61, 66, 67] . With the addition of this short disintegrin domain, only 77 amino acids long, full substrate binding specificity is restored to the metalloprotease domain [60, 67] . Also, despite low-relative efficiency, specific proteolytic activity is restored to the cleave site [60] . Unlike the metalloprotease domain, a crystal structure is available for the disintegrin domain as well as the following domains in the distal region [68, 69] . There is little secondary structure. There are two antiparallel b-sheets, a single N-terminal a-helix, and four disulfide bridges [68] . These disulfide bridges maintain the structure of the domain [68] . The Cys322-Cys347 disulfide bridge is well conserved throughout other crystalized ADAM proteases [70, 71] . Within this domain, two hydrophobic residues and one charged residue have been identified to bind to VWF. Glycine substitutions on Val352 and Leu350 produce, respectively, a four/five-fold and 10/20-fold reduction in catalytic efficiency in cleavage to VWF115 [67] . Similarly, an alanine substitution mutation introduced within the Arg349 residue decreased catalytic efficiency of cleavage of VWF115 by 20-fold [67] . The valine and leucine residues are hypothesized to interact in a hydrophobic manner and arginine in an ionically to Ala1612 and Asp1614 on VWF, respectively (Fig. 2b) [67] .
The third domain in ADAMTS13 is the first TSP-1 repeat. This central TSP-1 repeat is very well conserved among ADAMTS family proteases. The domain has only three antiparallel strands, two of which are b-sheets, and the whole domain is capped by disulfide bonds on each end [68] . These strands are stabilized by a 'CWR-layered core' (cysteine, tryptophan, and arginine) [68, 72] . The TSP-1 region is involved in substrate recognition [62] . When using a chimeric ADAMTS13/ADAMTS5 protease, replacing the cysteine rich and spacer domain in the metalloprotease domain, disintegrin-like domain, thrombospondin type-1 motif, cysteinerich domain, and spacer domain (MDTCS), with analogous domains from ADAMTS5, reduced the enzymatic efficiency two-fold; however, replacing the cysteine-rich domain, spacer domain, along with the TSP-1 region, with ADAMTS5 analogs, the enzymatic efficiency dropped nearly nine-fold [62] . This illustrates the contribution of TSP-1 region to binding of VWF. However, these weak interactions with Gln1624-Val1630 become less imperative when the cysteine-rich and spacer domains are bound [62, 66] .
The cysteine-rich and disintegrin region are very structurally similar, despite the low-sequence identity (17%). The cysteine-rich domain only has a short a-helix and two pairs of double stranded antiparallel b-sheets and the structure is stabilized by six disulfide linkages [68] . Recently, residues Gly471-Val474 at the base of the variable loop within the cysteine-rich domain have been identified to form a hydrophobic pocket that appears to be involved in the binding to hydrophobic residues Ile1642, Trp1644, Ile1649, Leu1650, and Ile1651 on VWF (Fig. 2c) [74] when the VWF exosite 2 is deleted, partially due to the absence of these hydrophobic interactions from the cysteinerich domain. Additionally, they found that the regions sequentially conserved within the ADAMTS family in the cysteine-rich domain are not necessary for substrate binding [73 && ]. Likewise, the charged region assigned the designation 'the unique loop', was not necessary for VWF115 cleavage [68, 73 && ]. The domain in ADAMTS13 that has the highest binding affinity for the A2 site of VWF is the spacer domain. The mechanism of VWF unwinding predicts that the exosite that binds to the spacer domain is the first exposed. This may allow the spacer domain to recognize the VWF exosite, even when VWF is only partially unfolded. The spacer domain and the cysteine-rich domain function closely with and similarly to one and other. A Leu621-Asp632 containing loop on the spacer domain has direct contact with the proximal portion of the cysteine-rich domain [68] . The spacer domain consists of 10 b-sheets that form a jellyroll topology [68] . This creates a hydrophobic cluster that is surrounded by arginine residues predicted to interact with Asp1596-Arg1659 on VWF (Fig. 2d ) [68] . When ADAMTS13 is cleaved before the spacer domain (i.e., construct MDTC), there is a four-fold drop in the K D for VWF73 peptide [60] . Additionally, the proteolytic efficiency of the MDTC fragment is decreased by 20-fold [61] . Structural predictions of the arginine surrounded hydrophobic cluster have been confirmed by several functional studies. Arg660, Tyr661, and Tyr665 together are essential for VWF binding and cleavage [75, 76] . These three residues are also very commonly found in the epitope site of ADAMTS13 antibodies [75, 76] .
The proximal domains (i.e., MDTCS) are all conserved within other ADAMTS proteases. However, within the further distal regions there are more variations between ADAMTS family proteases. These distal C-terminal regions of ADAMTS13 have not yet been crystalized, and much less is known about the structure and function.
Although the TSP-1 repeat between the disintegrin and cysteine-rich domains is well conserved within the ADAMTS proteases, the arrangement and number of the TSP-1 repeats following the spacer domain varies. Unlike the TSP1-1 repeat preceeding the spacer, the sequences of other TSP-1 repeats are not well conserved. Also, the fourth of these TSP-1 repeats has two cyseteines that are predicted to be unpaired [46] . Multiple TSP-1 repeats contain a CSVSCG (cysteine, serine, valine, serine, cysteine, glycine) motif. The second serine in this motif is glycosolated on the available side chain oxygen and the CSVSCG motif can bind the cell surface receptor CD36 [46, 77] .
ADAMTS13 is the only known ADAMTS protease that has two CUB domains at the distal C-terminus. The namesake protein is involved in developmental regulation [78] . Yet, the absence of the TSP-1 2-8 and the CUB domains has no negative impact upon the protease function of ADAMTS13 for VWF73 or VWF115, instead the C-terminal regions are necessary for binding globular VWF and VWF in shear conditions [79, 80] . When the TSP-1 2-8 repeats and the CUB domains are truncated the remaining domains (i.e., MDTCS) still cleave VWF substrates. In fact, recent studies suggest that MDTCS may cleave VWF73 with greater efficiency ($2-fold) than full-length ADAMTS13, with respective k cat /K m values of 2.0 AE 0.6 mmol/l À1 s
À1
and 0.75 AE 0.16 mmol/l À1 s À1 [61] . The CUB domains independently have no measurable affinity for VWF [81] . However, in the presence of shear stress, the CUB1 peptide will inhibit proteolysis of VWF [82] .
The CUB domains have a negative regulatory function of ADAMTS13 activity. A full-length recombinant ADAMTS13 has been imaged through both quick-freeze, deep-etch electron microscopy and transmission electron microscopy and it appears that the distal portion of ADAMTS13 folds inwards [83 && ,84 && ]. This suggests that when the C-terminal portions of ADAMTS13 are not bound to VWF the TSP-1 2-8 repeats fold the CUB domains toward the spacer domain [83
&& ]. The removal of these CUB domains, which does not allow for the interaction of CUB domains with the spacer domain, would grant greater access to VWF by the spacer domain [83 && ]. The C-terminal domains of ADAMTS13 may have regulatory functions entirely unrelated to the proteolytic activity. Five thiol groups within TSP-1 repeats 2-8 and CUB-1 domain potentially form disulfide bonds with VWF anchoring the enzyme to full-length VWF [85] . These disulfide interactions between ADAMTS13 and full-length VWF, as well as ADAMTS13-VWF complexes, have not been well described [79, 85] . Yet, interestingly, these free thiol interactions of the distal regions appear to have antithrombotic activity independent of the proteolytic functions of ADAMTS13 [86 && ]. Furthermore, mice lacking TSP-1 7-8 and CUB domains are more thrombogenic in high shear conditions [87] , consistent with the importance of more distal C-terminal domains for function in vivo.
ANTIBODY SPECIFICITY
The presence of anti-ADAMTS13 antibodies and their epitopes has been well studied in recent years. Not all anti-ADAMTS13 antibodies disrupt the cleavage of VWF by ADAMTS13 [88] . Notably, the presence of anti-ADAMTS13 antibodies that do disrupt VWF cleavage is not always sufficient for the onset of acquired TTP, suggesting the requirement of other potential triggers for its onset [88, 89 && ]. Autoantibody epitope mapping has not only further characterized the mechanism of the disease, but also uncovered the structure-function relationship of ADAMTS13. Most acquired TTP patients have multiple anti-ADAMTS13 antibodies that bind to several domains [89 && , [90] [91] [92] [93] . Binding epitopes, including residues Glu376, Gln159-Asp166, Tyr 305-Glu327, and Asn308 in the metalloprotease and disintegrin domains have been identified [91] . However, the most frequent antibody epitope region is found within the cysteine-rich and spacer domain, particularly the spacer domain [75, [90] [91] [92] [93] [94] [95] 96 && ,97]. In the mapping of the antigenic regions on ADAMTS13, the most common characteristic is the involvement of five loops located on the spacer domain (Fig. 3a) . In one study using the MDTCS variant, modifications to only five residues in the spacer domain Arg660, Tyr661, Tyr 665, Arg568, and Phe592 antibody binding is strongly diminished in 46 of 48 TTP patients [90] . These residues represent three of the five-epitope loops on the spacer domain.
With the understanding of the spacer domain function, and common antigenic-binding sites, gain of function (GoF) mutation (R660K/F592Y/R568K/ Y661F/Y665F) was made to ADAMTS13 (Fig. 3c ) [83 && ,98] . This gain of function (GoF) mutation is both resistant to many antibody interactions and does not lose any catalytic efficiently compared with wild-type ADAMTS13 [83 && ,98] . This and other GoF mutations offer exciting possibilities in the treatment of acquired TTP. Continuing in this direction, furthering the characterization and catalogue of anti-ADAMTS13 antibodies and their epitopes will likely lead to greater understandings of ADAMTS13 function and novel therapies for TTP.
CONCLUSION
Tremendous progress has been made in the past decade toward our understandings of the structure-functional relationship of ADAMTS13. However, animal models or humans studies may be necessary to translate the biochemical activity of ADATMS13 and its variants with their in-vivo biological functions under pathophysiological conditions. Acknowledgements None.
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